XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Collaborations - Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 36,810 $ 42,307 $ 99,973 $ 100,378
General and administrative 12,591 12,469 44,040 36,917
Total operating expenses 49,401 54,776 144,013 137,295
Incyte        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront payments 4,371 4,045 12,912 12,677
Reimbursement revenue 1,547 2,300 4,248 6,514
Milestones 3,479 0 5,980 1,000
Other 0 0 0 0
Total collaboration revenue 9,397 6,345 23,140 20,191
Operating expenses:        
Research and development 0 162 24 712
General and administrative 0 0 0 0
Total operating expenses 0 162 24 712
Revenue recognized in the period 4,371 4,045 12,912 12,677
Lilly        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront payments 789 (551) 8,270 7,634
Reimbursement revenue 847 787 3,543 2,823
Milestones 0 0 0 0
Other 0 0 0 0
Total collaboration revenue 1,636 236 11,813 10,457
Operating expenses:        
Research and development 0 0 0 0
General and administrative 0 0 0 0
Total operating expenses 0 0 0 0
Revenue recognized in the period 789 (551) 8,270 7,634
Other        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront payments 0 0 0 222
Reimbursement revenue 0 0 0 0
Milestones 0 0 0 0
Other 0 0 0 50
Total collaboration revenue 0 0 0 272
Operating expenses:        
Research and development 0 0 0 0
General and administrative 0 0 0 0
Total operating expenses 0 0 0 0
Revenue recognized in the period 0 0 0 222
Collaboration Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront payments 5,160 3,494 21,182 20,533
Reimbursement revenue 2,394 3,087 7,791 9,337
Milestones 3,479 0 5,980 1,000
Other 0 0 55 50
Total collaboration revenue 11,033 6,581 35,008 30,920
Operating expenses:        
Research and development 0 162 24 712
General and administrative 0 0 0 0
Total operating expenses 0 162 24 712
Revenue recognized in the period $ 5,160 $ 3,494 $ 21,182 $ 20,533